Key Points
- CEO Katherine Stueland sold 2,172 shares at an average price of $65.19 on April 29 for $141,592.68 to cover tax withholding from vested equity, trimming her stake by 2.28% to 93,216 shares (about $6.08M).
- Stueland has recently executed several much larger sales in March (46,933 shares on Mar 26, 17,179 on Mar 16 and 25,459 on Mar 4), amounting to multi‑million dollar dispositions and signaling a pattern of insider selling.
- GeneDx shares trade near $65 with a $1.91B market cap and 50/200-day averages of $71.45/$107.37; analysts hold a consensus of Moderate Buy with an average price target of $134.17 and institutional ownership at 61.72%.
GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CFO Kevin Feeley sold 392 shares of the business's stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $65.19, for a total transaction of $25,554.48. Following the transaction, the chief financial officer directly owned 34,942 shares in the company, valued at $2,277,868.98. This trade represents a 1.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Kevin Feeley also recently made the following trade(s):
- On Monday, March 16th, Kevin Feeley sold 5,706 shares of GeneDx stock. The shares were sold at an average price of $76.80, for a total transaction of $438,220.80.
- On Wednesday, March 4th, Kevin Feeley sold 6,187 shares of GeneDx stock. The shares were sold at an average price of $78.61, for a total transaction of $486,360.07.
GeneDx Price Performance
Shares of GeneDx stock opened at $65.38 on Friday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.34 and a current ratio of 2.46. The firm's 50-day simple moving average is $71.45 and its 200-day simple moving average is $107.37. GeneDx Holdings Corp. has a twelve month low of $55.17 and a twelve month high of $170.87. The firm has a market cap of $1.91 billion, a P/E ratio of -87.17 and a beta of 2.06.
GeneDx (NASDAQ:WGS - Get Free Report) last posted its earnings results on Monday, February 23rd. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.03. GeneDx had a negative net margin of 4.92% and a positive return on equity of 14.73%. The business had revenue of $120.99 million for the quarter, compared to analyst estimates of $120.80 million. As a group, research analysts expect that GeneDx Holdings Corp. will post 0.75 EPS for the current fiscal year.
Institutional Trading of GeneDx
A number of hedge funds have recently modified their holdings of the company. Arizona State Retirement System raised its position in shares of GeneDx by 2.1% in the 4th quarter. Arizona State Retirement System now owns 5,594 shares of the company's stock valued at $728,000 after acquiring an additional 113 shares during the period. Cerity Partners LLC raised its position in shares of GeneDx by 6.0% in the 4th quarter. Cerity Partners LLC now owns 2,527 shares of the company's stock valued at $329,000 after acquiring an additional 142 shares during the period. Main Management ETF Advisors LLC raised its position in shares of GeneDx by 1.0% in the 4th quarter. Main Management ETF Advisors LLC now owns 15,660 shares of the company's stock valued at $2,037,000 after acquiring an additional 160 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of GeneDx by 5.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,702 shares of the company's stock valued at $399,000 after acquiring an additional 181 shares during the period. Finally, Jones Financial Companies Lllp raised its position in shares of GeneDx by 664.3% in the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company's stock valued at $25,000 after acquiring an additional 186 shares during the period. 61.72% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on WGS shares. Weiss Ratings reissued a "sell (d)" rating on shares of GeneDx in a report on Wednesday, January 21st. Guggenheim decreased their price objective on shares of GeneDx from $170.00 to $100.00 and set a "buy" rating on the stock in a report on Monday, March 30th. Jefferies Financial Group set a $150.00 price objective on shares of GeneDx in a report on Monday, February 23rd. Piper Sandler reissued an "overweight" rating and set a $130.00 price objective (down from $160.00) on shares of GeneDx in a report on Tuesday, February 24th. Finally, Wells Fargo & Company upgraded shares of GeneDx from an "equal weight" rating to an "overweight" rating and set a $155.00 target price on the stock in a research report on Monday, February 9th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $134.17.
Read Our Latest Stock Analysis on WGS
GeneDx Company Profile
(
Get Free Report)
GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx's laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.
Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
